2026-10-14T05:50:40Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34055107 2026-10-02T07:20:10Z category_37339 category_37360 category_37363 portal_1012 item_type_3 month_year_10_2026

Table 2 from JNJ-79032421, a Novel Membrane-Restricted Mesothelin-Targeting T Cell–Engaging Bispecific Antibody for the Treatment of Mesothelin-Positive Cancers Karine Smans (25300309) Thomas Nesspor (25300312) Sabine De Breucker (25300315) Erika van Heerde (25300318) Annemie Valckx (25300321) Nele Van Slycken (25300324) Katrin Sproesser (25300327) Bethany Mattson Cypert (25300330) Kathryn Packman (15090061) Gerald Chu (21233104) Jamie Fisher (25300333) Nicholas Mazzanti (25300336) Ted Petley (25300339) Winnie Chan (25300342) Brian Del Rosario (25300345) Tun Liu (25300348) Stuart Ember (25300351) Paul L. Shaffer (25300354) Jacalyn S. Clawson (25300357) Joshua M. Bauml (15017586) Sheri Moores (25300360) Sylvie Laquerre (25300363) Paul R. Gavine (25300366) Cancer Therapeutic Research and Development Immuno-oncology Biological Agents & Therapies Bispecific antibodies Drug Targets Cell surface receptor drug targets Gynecological Cancers Ovarian cancer Immunotherapy Lung Cancer Pharmacology Cellular pharmacology Molecular pharmacology <p>Geomean EC₅₀ values (nmol/L, <i>n</i> = 2 experiments) for high- [MNC3B321 (nmr) and MNC3B319 (mr)] and low-affinity [MNC3B597 (nmr) and JNJ-79032421 (mr)] MSLNxCD3 BsAbs T cell–induced cytotoxicity against OVCAR-8 (MSLN^HI+), OVCAR-8 K1/C8 (MSLN^MED+), and SK-OV-3 (MSLN^LO+) cells in the presence of sMSLN.</p> 2026-10-02T00:00:00Z Dataset Dataset 10.1158/1535-7163.34055107 https://figshare.com/articles/dataset/Table_2_from_JNJ-79032421_a_Novel_Membrane-Restricted_Mesothelin-Targeting_T_Cell_Engaging_Bispecific_Antibody_for_the_Treatment_of_Mesothelin-Positive_Cancers/34055107 CC BY